Thrombo inCode® is a genetic test that evaluates the risk of thrombosis associated with hereditary thrombophilia and a patient’s risk factors. Genetics contribute to around 50% of the development of a venous thromboembolism event and interact with a number of transient factors that can increase the risk of thrombosis. That is why it is important to determine the thrombohilic profile of the patients with personal and family histories of thrombosis to adjust their treatment and take preventive measures if necessary. Thrombo inCode puts the patient’s genetic and clinical information into an algorithm, initiating a comprehensive analysis of their venous thrombosis risk, rendering results and recommendations that are clinically useful in their therapeutic management.


Thrombo inCode® analyzes 12 variants of the Single Nucleotide Polymorphism (SNPs) type in seven genes, identified in Genome-Wide Association studies or GWAs. They are related with hereditary thrombophilia and have a causal and functional effect on the mechanisms involved in blood coagulation. They are grouped in a panel of scientifically-validated diagnostic value.


  • Patients with a personal background of venous thromboembolism
  • Patients with family or personal histories of venous thromboembolism who are going to be subjected to prothrombotic risk situations
  • Family members of individuals in whom specific thrombophilic variants have been identified (family study)


Thrombo inCode® has proven to have a greater diagnostic capacity, with a statistically significant difference in comparison with the Factor V Leiden and Prothrombin variants. It has been recognized as the “gold standard” in publications of reference for thrombosis risk assessment.

In addition to diagnosing hereditary thrombophilia, the algorithm that processes the patient’s genetic information with their clinical factors makes it possible to determine how likely they are to develop a thromboembolism in different risk situations.


  • Soria JM, et al. Multilocus Genetic Risk Scores for Venous Thromboembolism Risk Assessment. J Am Heart Assoc. 2014;3(5):e001060
  • Rubio-Terrés C, et al. Economic Analysis of Thrombo inCode, a Clinical–Genetic Function for Assessing the Risk of Venous Thromboembolism. Appl Health Econ Health Policy. 2015 Apr;13(2):233-42
  • Dobnic F et al. Guía de práctica clínica para la prevención, diagnóstico y tratamiento de la enfermedad tromboembólica venosa en el deporte. Apunts Med Esport 2015;50(188):147-159
  • Muñon Marin AJ et al. Multivariable clinical-genetic risk model for predicting venous thromboembolism events in patients with cancer. British Journal of Cancer 2018;118:1056-1061

More information

Send us your details and request through this form and we will reply soon.

    GENinCode shall respond to requests for information, products and / or services and registration to events, as well as send commercial and legal communications deemed appropriate to the client. You may exercise your rights of access, rectification, cancellation, destruction or, opposition, or limit the treatment of data transfer at any time by notifying GENinCode - For further information please view our privacy policy here.